Alembic Pharmaceuticals Ltd

💊 Alembic Pharma Secures USFDA Approval for Generic Gilenya Capsules

• Final USFDA approval received on April 25, 2026

• Generic equivalent to Novartis' Gilenya Capsules for treating multiple sclerosis

• Market size estimated at US$145 million for 12 months ending December 2025

• Indicated for relapsing forms of multiple sclerosis in patients 10 years and older

• Marks Alembic's 237th ANDA approval from USFDA (219 final approvals, 18 tentative approvals)